In a treatment-naive patient with chronic hepatitis B, a personalized approach allows treatment efficacy to be optimized. Firstly, the selection of good candidates for therapy is crucial. Patients with chronic active hepatitis B -with relatively low levels of HBV DNA replication (<10 9 copies/ml) and relatively high alanine aminotransferase (ALT) levels -are good candidates for therapy. By contrast, patients with chronic hepatitis B in the immunotolerance phase, who have high levels of HBV DNA and persistently normal ALT levels, as well as inactive hepatitis B surface antigen (HBsAg) carriers with low HBV DNA and normal ALT levels do not have an indication for therapy as they are poor responders. Secondly, the characteristics of the patient (for example, gender, age, immune status, general health status and comorbidities), the characteristics of the liver disease (for example, presence of cirrhosis and liver function) and the characteristics of the virus (for example, genotype) are important when assessing the chance of success and when choosing the best therapeutic strategy (nucleoside/ nucleotide analogue or interferon). Thirdly, during therapy, the antiviral effect -assessed by decrease in HBV DNA level -allows an individualized response-guided approach. In addition, quantification of HBsAg after 3-6 months of interferon therapy appears to be a good predictor of sustained virological response after treatment and HBsAg clearance. Continuing interferon therapy until week 48 is justified in patients with a significant decrease in HBsAg. Ongoing and future studies will provide useful information regarding prolonging interferon therapy beyond 48 weeks in some patients in order to increase efficacy, and also regarding the role of combination therapy with interferon and potent nucleoside/nucleotide analogues, such as entecavir or tenofovir disoproxil fumarate.
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Chronic hepatitis B (CHB) is one of the most common chronic liver diseases, leading to high rates of morbidity and mortality resulting from the development of cirrhosis and hepatocellular carcinoma [1] . More than 350 million people -5% of the global population -suffer from HBV infection [2, 3] . In recent years, marked progress has been made in the treatment of CHB. Currently, there are several approved therapies in Europe and the US, including three formulations of interferon (IFN)-α (conventional IFN-α and pegylated interferon [PEG-IFN]-α2a and -α2b) and five nucleoside/nucleotide analogues (NAs; lamivudine, adefovir dipivoxil [ADV], entecavir, telbivudine and tenofovir disoproxil fumarate [TDF] ). Recent data and recommendations allow a more personalized approach for optimizing treatment in individual patients.
Who to treat?
It is difficult to completely eradicate HBV infection because of the persistence of covalently closed circular DNA in the nuclei of infected hepatocytes. Short-term goals of treatment are limited to virological end points of hepatitis B e antigen (HBeAg) seroconversion and reduction of HBV DNA to undetectable levels, as well as normalization of serum alanine aminotransferase (ALT) levels. Long-term goals, such as prevention of cirrhosis and hepatocellular carcinoma, and improved survival, are more important, but are achievable only if treatment results in a durable virological response with the lowest level of HBV DNA possible. Loss of hepatitis B surface antigen (HBsAg) and seroconversion to antibody against HBsAg (anti-HBs) remains the Review A personalized approach to optimize hepatitis B treatment in treatment-naive patients Introduction ultimate goal of antiviral therapy, indicating a complete response and resolution of the disease [2] . However, loss of HBsAg occurs infrequently with current antiviral therapy: in 3% of patients at 6 months post-treatment following a 48-week course of PEG-IFN-α2a and in 1-3% of patients receiving 1 year of NA therapy [4, 5] .
Selecting patients who should be treated is a crucial step before choosing the treatment strategy. In this respect, current guidelines recommend that HBeAgpositive patients with mild disease, that is, high HBV DNA levels and normal ALT ('immune tolerant' patients) and HBV carriers who are either HBeAg-positive or HBeAg-negative with normal ALT and low HBV DNA levels (<2,000 IU/ml; 'inactive carriers') do not require immediate treatment and should be monitored every 3-6 months [2, 5, 6] . Treatment should be considered for HBeAg-positive and HBeAg-negative patients when serum ALT levels are greater than the upper limit of normal, HBV DNA levels are >2,000 IU/ml, and liver biopsy shows active inflammation and/or fibrosis [2] .
How to treat?
There are two general approaches to therapy of CHB: one using a defined, self-limited course of 4-12 months of conventional IFN or 48 weeks of PEG-IFN-α2a, and the other using long-term, continuous therapy with NAs.
PEG-IFN-α therapy
IFN has antiviral, antiproliferative and immunomodulatory effects and was used in the treatment of CHB for many years. A meta-analysis including 15 randomized controlled trials demonstrated the superiority of conventional IFN-α over placebo with regards to the undetectability of HBV DNA (37% versus 17%) and HBeAg loss (33% versus 12%) [7] . PEG-IFN-α2a has replaced the use of conventional IFN-α in CHB because of its more convenient once-weekly administration and greater potency: PEG-IFN-α2a resulted in a steeper decrease in HBV DNA levels and a higher rate of HBeAg seroconversion (33% versus 25%) when compared with conventional IFN-α [8] . PEG-IFN-α2a is the licensed form of PEG-IFN for the treatment of CHB in Europe and the US [2, 6] . The efficacy of PEG-IFN-α2a in HBeAg-positive and HBeAg-negative patients has been established in two large pivotal trials including 814 and 552 patients, respectively [9, 10] , and similar efficacy has been reported with use of PEG-IFN-α2b [11] . In both studies, PEG-IFN-α2a monotherapy, the combination of PEG-IFN-α2a plus lamivudine and lamivudine monotherapy were compared during a 48-week treatment course. At the end of a 6-month post-treatment follow-up period, HBeAg seroconversion rates were 32%, 27% and 19%, respectively, in the HBeAg-positive study [9] and serum HBV DNA levels were <400 copies/ ml in 19%, 20% and 7% of patients, respectively, in the HBeAg-negative study [10] .
Recently, long-term follow-up data were reported for a subgroup of patients enrolled in the HBeAgnegative trial [12, 13] . Interestingly, sustained offtreatment response (HBV DNA<400 copies/ml) was maintained in 18% of patients treated with PEG-IFNα2a. Importantly, HBsAg clearance occurred with a high steady rate (>10% per year) in sustained virological responders -reaching 64% at 5 years posttreatment. These findings confirm those observed in the long-term conventional IFN-α studies [14] , and are in accordance with the dual antiviral and immunomodulatory effects of PEG-IFN-α2a, which result in not only the suppression of viral replication, but also the clearance of infected hepatocytes.
Finally, multivariate analysis showed that high baseline ALT, low baseline HBV DNA and low concentrations of pretreatment HBeAg were pretreatment predictors of HBeAg seroconversion in HBeAg-positive patients. Similarly, predictors of sustained virological response (SVR) -defined as undetectable serum HBV DNA after withdrawal of therapy in HBeAg-negative patients -included low baseline HBV DNA, younger age and HBV genotype A [15] .
Despite the advantage of PEG-IFN-α2a in inducing SVR in nearly 20% of patients after a limited course of treatment and a high steady rate of HBsAg clearance in patients with an SVR, the use of PEG-IFN-α2a currently accounts for no more than 10% of all prescriptions for CHB treatment in Europe and the US. This low usage pattern might be related to the side effects of PEG-IFN-α2a and the need for its administration by injection. Interestingly, recent data have demonstrated that PEG-IFN-α2a has a better tolerability profile in CHB than in hepatitis C, with a lower incidence of common IFN-related adverse events and a significantly lower incidence of depression being reported [16] . The NEPTUNE trial is currently investigating the efficacy and safety of a shorter course (24 weeks) and lower dose (90 µg) of PEG-IFN-α2a in patients with HBeAgpositive CHB. If shown to provide equivalent efficacy to the current standard of care, such strategies have the potential to further improve tolerability and the attractiveness of treatment to patients and clinicians.
NA therapy
NAs inhibit the viral polymerase activity by different mechanisms of action. Depending on the drug, this inhibitory activity can affect the priming of reverse transcription and the elongation of viral minus or plus strand DNA. All NAs are competitive inhibitors of the natural endogenous intracellular nucleotide. Their incorporation into nascent viral DNA results in premature chain termination by preventing the incorporation of the next nucleotide in the viral DNA strand. The past decade has witnessed a shift in the treatment paradigm from timelimited therapy with IFN-α to the now relatively common practice of long-term HBV suppression with NAs. The reasons for this shift are explained by the finding that NAs, especially the newer agents, such as entecavir and TDF, are more effective in suppressing HBV replication and less likely to be associated with drug resistance than the original NAs. In addition, they are administered orally and have excellent safety profiles. However, NAs need to be administered indefinitely because withdrawal of therapy is generally associated with viral reactivation. Moreover, a major concern with long-term NA therapy is the selection of antiviral-resistant mutants leading to viral breakthrough. The rate at which resistant mutants are selected is related to pretreatment serum HBV DNA level, rapidity of viral suppression, duration of treatment, and prior exposure to NAs.
Lamivudine
Lamivudine was the first oral drug approved for the treatment of CHB, and it remains in widespread use worldwide. However, lamivudine has a poor resistance profile, with 23% of patients developing resistance in the YMDD domain of the DNA polymerase (codon rtM204V/I/S) at year 1 of therapy, increasing to 46% at year 2, 55% at year 3, and then 65-71% at years 4 and 5 [17] .
Adefovir dipivoxil ADV, a nucleotide analogue, was the second oral agent introduced for the treatment of CHB. Despite its improved resistance profile over lamivudine, when used at the licensed dose of 10 mg daily, this agent actually has a lower degree of viral suppression than lamivudine. This dose was used because of nephrotoxicity associated with higher doses. In the pivotal trials, HBV DNA undetectability at 1 year was attained in 21% and 51% of HBeAg-positive and HBeAg-negative patients, respectively [18, 19] . HBeAg seroconversion occurred in 12% of patients after 1 year, but the rate progressively rose to 48% after 5 years [20] . ADV has a far better resistance profile than lamivudine, with cumulative genotypic resistance rates of 0% and 3% at 1 and 2 years, respectively, although the rate of genotypic resistance rises to 29% after 5 years in HBeAg-negative patients [21] . However, in patients with HBV DNA<1,000 copies/ml at 1 year, the 4-year resistance rate was only 4% [22] .
Entecavir
Entecavir is a potent anti-HBV agent. In 1-year pivotal studies, entecavir 0.5 mg daily suppressed HBV DNA to undetectable levels in 67% of HBeAg-positive and in 90% of HBeAg-negative patients, respectively, compared with 36% and 72%, in lamivudine-treated patients [23, 24] . Despite this potent antiviral efficacy, the HBeAg seroconversion rate was relatively low and similar to that observed with other oral NAs (21% and 18% with entecavir and lamivudine, respectively). Long-term observations in a subgroup of the HBeAg-positive patients from this study demonstrated a cumulative rate of HBV DNA clearance of >90% after 4 years. Interestingly, a very low rate of entecavir resistance was observed in treatmentnaive patients after 5 years of therapy with a cumulative genotypic resistance rate of 1.2% at 5 years in lamivudine-naive patients [25] . In lamivudine-resistant patients, by contrast, approximately 35% of patients developed resistance to entecavir 1.0 mg daily within 3 years of being switched to entecavir [26] . This difference is a result of the high genetic barrier to resistance of entecavir that requires the initial selection of rtM204I/V mutations (lamivudine-resistant mutations), followed by additional 'signature' entecavir-associated mutations at the rtI169, rtM250, rtT184 or rtS202 loci. Once the secondary substitutions emerge, high-level resistance to entecavir occurs; therefore, entecavir monotherapy is now regarded as a suboptimal choice for lamivudine-resistant patients.
Telbivudine
Telbivudine is a new potent agent administered at the dose of 600 mg daily in pivotal trials [27] . After 1 year of treatment, HBV DNA was undetectable in 60% of HBeAg-positive and 88% of HBeAg-negative patients. HBeAg seroconversion occurred in 23% of telbivudine recipients at 1 year compared with 21% of lamivudine recipients. The resistance profile of telbivudine is superior to that of lamivudine, but there is still a risk of resistance: 5% and 2% after 1 year in HBeAg-positive and HBeAg-negative patients, respectively. Most notably, the rate of resistance at week 92 was 4% in HBeAgpositive patients and 2% in HBeAg-negative patients who had undetectable HBV DNA at week 24. By contrast, 30-60% of both HBeAg-positive and HBeAgnegative patients developed telbivudine resistance after 92 weeks if they had HBV DNA>4 log 10 copies/ml at week 24, with intermediate rates of resistance for patients with lower residual viraemia at week 24 [28] .
Tenofovir disoproxil fumarate TDF is a nucleotide analogue that differs from ADV by the presence of one methyl group. It was approved for the treatment of HIV in 2002, and for HBV in April 2008 in Europe and in August 2008 in the US. Recent data from pivotal large randomized comparative trials have shown that TDF 300 mg daily is associated with impressive rates of viral suppression at 48 weeks of therapy in HBV-monoinfected patients [29] . In these studies, 76% of HBeAg-positive patients and 93% of HBeAg-negative patients had undetectable HBV DNA by PCR analysis after 48 weeks of TDF therapy compared with only 13% and 63% of ADVtreated HBeAg-positive and HBeAg-negative patients, respectively. In HBeAg-positive patients, HBeAg seroconversion was achieved by 21% of TDF-treated patients, a rate not significantly different to that seen with ADV (18%; P=0.36). Recent 3-year data demonstrated HBV DNA undetectability in 79% and 91% of HBeAg-positive and HBeAg-negative patients, respectively [30] . No clearly defined genotypic resistance or viral breakthroughs related to resistance have been observed.
NAs or PEG-IFN-α2a therapy?
PEG-IFN-α2a might be preferred as a first-line therapy, especially in patients with a favourable genotype, such as genotype A (or B), given the advantage of inducing SVR in nearly 20% of patients after a limited course of treatment and a high steady rate of HBsAg clearance in SVRs. By contrast, treatment with NAs often involves long-term commitment, without a clearly defined end point of therapy. Should a virological response not be achieved with PEG-IFN-α2a, NA therapy can be used without increasing the probability for later drug failure. The same cannot be said for sequential NA therapy because selection pressures for drug-resistant HBV mutants during treatment with one drug (for example, lamivudine) might facilitate emergence of resistance to another (for example, entecavir). In clinical practice, PEG-IFN-α2a could be used as a first-line therapy in patients with good predictors of response, including younger age, higher baseline ALT levels, lower baseline HBV DNA levels and genotype A infection. The other option is to start with a potent NA with a high genetic barrier to resistance, such as entecavir or TDF [2, 6] . Although telbivudine can be considered in patients with relatively low replication levels, it is probably not desirable as the first-line therapy. In countries where cost is an issue, lamivudine might still play a role. Although NA-based therapy is increasingly preferred by clinicians because of its ease of administration and minimal side effects, careful follow-up is necessary to monitor response and emergence of resistance.
De novo monotherapy or combination therapy?
The observation of emergent resistance with HBV therapy, and the cumulative experience with HIV therapy, has led to the suggestion that combination therapy for HBV should be routine. However, recommendations for combination therapy are limited by the lack of clinical investigations and reliable information on long-term safety. Furthermore, the much slower incidence of HBV resistance and recent reports of lower rates of long-term resistance with newer agents, such as entecavir and TDF, favour first-line monotherapy.
Combination therapy could be considered as secondline therapy in patients who have developed resistance.
How to manage patients on treatment
PEG-IFN-α2a therapy can be optimized if reliable early on-treatment predictors of SVR are identified -similar to the stopping rule of early virological response used in chronic hepatitis C therapy. Indeed, major reasons for the decreased use of PEG-IFN-α2a are its relatively lower antiviral potency compared with NAs, and the substantial side effects. Therefore, it would be of great clinical relevance to identify, as early as possible, those patients who are likely to develop SVR and, more importantly, relapsers and non-responders who might benefit from switching to an alternative treatment strategy with an NA. In this respect, on-treatment serum HBeAg level was recently used as a quantitative tool to predict SVR to PEG-IFN-α2a, and demonstrated high negative predictive values at weeks 12 and 24 of therapy [31] . In addition, early HBeAg loss during PEG-IFN-α2b therapy has been shown to be associated with response during long-term follow-up [32] . Interestingly, a recent pilot study in HBeAg-negative patients demonstrated that a significant decrease in serum HBsAg level (>0.5 log 10 IU/ml) at week 12 of therapy has a strong predictive value [33] . This hypothesis has been confirmed by a retrospective analysis of the pivotal study of PEG-IFN-α2a in HBeAg-negative patients [34] . The on-treatment kinetics of HBsAg seems to be influenced by HBV genotype with a more rapid decrease in patients infected with genotype A [35] . The use of quantitative HBsAg at week 12 or week 24 of PEG-IFN-α2a therapy could be useful in predicting the probability of SVR and HBsAg clearance. There are fewer data on the potential of on-treatment monitoring of HBsAg levels for predicting response to NA therapy, although there is some evidence that quantitative HBsAg might predict eventual HBsAg clearance [36] .
Predicting resistance: early virological response
In a study of lamivudine-treated patients, Yuen et al. [37] demonstrated that if HBV DNA was undetectable (<10 3 copies/ml) at week 24, 13% of patients had virological breakthrough caused by resistance at a mean of 120 weeks, compared with 63% of those with HBV DNA levels ≥10 3 copies/ml at week 24. In the pivotal ADV trial, only 4% of patients with undetectable HBV DNA (<10 3 copies/ml) at week 48 had resistance 4 years later compared with >40% of those with HBV DNA≥10 3 copies/ml at week 48 [22] . The largest database evaluating this concept comes from the GLOBE trial, where HBeAg-positive patients were shown to have a resistance rate of 2% at week 104 if HBV DNA was undetectable at week 24, whereas HBeAg-negative patients with initial HBV DNA<10 7 copies/ml had a week 104 resistance rate of 1.8% if HBV-DNA-negative at week 24 [26] . From these data emerges the concept that if lamivudine or telbivudine is selected as initial therapy, they remain acceptable as therapeutic options only if HBV DNA is undetectable with a sensitive assay by week 24 [2] . Even slight viraemia at week 24 is associated with an unacceptable rate of subsequent resistance at 1 and 2 years. With drugs that have a higher genetic barrier to resistance (such as entecavir and TDF), there are fewer data linking the predictive value of HBV DNA levels to long-term outcomes in treatment-naive patients because of the absence or very low rate of resistance reported to date with these agents. In particular, it has been recently reported that entecavir is associated with a longterm genotypic resistance rate of 1.2% after 5 years in treatment-naive patients, which clearly indicates a robust resistance profile. Long-term resistance data on TDF are needed, but the absence of any genotypic resistance in the pivotal trials at year 3 is promising. However, even with these later drugs, verifying the absence of detectable HBV DNA at 1 year of therapy is recommended [2] .
On-treatment assessment of patients on NAs is useful in the context of assuring drug compliance and for optimizing treatment in patients receiving NAs with a lower genetic barrier of resistance, such as lamivudine and telbivudine. However, the latter approach would be a suboptimal treatment strategy because potent drugs with a high genetic barrier of resistance, such as entecavir or TDF, exist. Although there is little evidence that these more potent dugs require treatment optimization through regular on-treatment assessment, similar to the less potent drugs, periodic monitoring is necessary to check for drug compliance and potential side effects (renal toxicity for TDF). Given the importance of early recognition and management of resistance, guidelines recommend that HBV DNA levels are monitored at least every 3-6 months in patients receiving NA therapy [2, 6] .
Switch therapy or add therapy?
Overall, there is a trend among many experts towards the use of combination therapy in patients with incomplete responses to monotherapy, instead of switching therapy. This is not because this approach has demonstrated additive viral suppression and potential minimization of the long-term risk of resistance, but is based on virological principles proven in other therapeutic settings, such as HIV. In this respect, studies have showcased a growing body of data indicating that when adefovir is added to lamivudine -instead of substituted for it -in lamivudine-resistant patients, it is rare for adefovir resistance to emerge within the first 3 years [38, 39] . By contrast, when patients are switched to ADV, 25% of lamivudine-resistant patients developed genotypic resistance to ADV within 2-3 years, indicating that sequential therapy might expose patients to the risk of selection of multidrug-resistant strains. This strategy might not be necessary in the era of new NAs, such as entecavir and TDF, which have lower resistance rates and high levels of potency. Current guidelines recommend the addition of a second drug without cross-reactivity in the case of resistance. For example, the addition of TDF (or ADV if TDF is unavailable) is recommended in cases of lamivudine, telbivudine or entecavir resistance, although it should be noted that the long-term safety of such combination regimens is unclear. However, TDF should not be added to ADV in cases of ADV resistance because of the possibility of cross-resistance [2] .
How to improve efficacy
Although a considerable amount of progress has been made in the past decade with regard to antiviral therapy of CHB, there is still a great unmet need for a drug therapy that results in durable virological remission in most patients after a finite period of treatment. The key to successful treatment of hepatitis B remains in the careful patient selection and individualized treatment decisions, which aim to achieve a response with the shortest course of therapy, thereby minimizing the potential for adverse events and limiting costs. Attempting to achieve HBsAg seroconversion is important because it is associated with a greater certainty of long-term benefit. Based on the available data, a 48-week course of PEG-IFNα2a could be a preferable first-line approach in younger individuals with other favourable predictors.
Recently the presence of a polymorphism upstream from the interleukin-28B gene, which encodes type-III IFN-λ has been shown to be associated with the innate response to HCV and to be highly predictive of a treatment-mediated response to PEG-IFN in patients treated for chronic hepatitis C infection [40] [41] [42] . It will be of interest to see if this or other polymorphisms might also affect, and be predictive of, response to IFN-based therapy in CHB.
Combination therapy of PEG-IFN-α2a with a potent NA might improve efficacy. The rationale for this strategy is that the viral suppression induced by a potent NA will decrease the synthesis and expression of viral proteins, which can optimize the immunomodulatory effects of PEG-IFN-α2a, resulting in clearance of infected cells. Indeed, this is the only combination strategy to date that has shown an additive effect on viral suppression [9, 10] . Moreover, PEG-IFN-α2a seems to play a 'protective' role against the development of resistant-mutants to NAs. Studies on the combination of PEG-IFN with the more potent NAs (entecavir or TDF) are obviously needed.
